Ledipasvir

Place Of Origin
China
Minimum Order
10
Packaging
vial
Delivery
15 Days

Ledipasvir Product Description :


Ledipasvir (formerly GS-5885) is a drug for the treatment of hepatitis C that was developed by Gilead Sciences.After completing Phase III clinical trials, on February 10, 2014 Gilead filed for U.S. approval of a ledipasvir/sofosbuvir fixed-dose combination tablet for genotype 1 hepatitis C. The ledipasvir/sofosbuvir combination is a direct-acting antiviral agent that interferes with HCV replication and can be used to treat patients with genotypes 1a or 1b without PEG-interferon or ribavirin.

Ledipasvir is an inhibitor of the hepatitis C virus NS5A protein.

Data presented at the 20th Conference on Retroviruses and Opportunistic Infections in March 2013 showed that a triple regimen of the nucleotide analog inhibitor sofosbuvir, ledipasvir, and ribavirin produced a 12-week post-treatment sustained virological response (SVR12) rate of 100% for both treatment-naive patients and prior non-responders with HCV genotype 1.The sofosbuvir/ledipasvir coformulation is being tested with and without ribavirin. In February 2014 Gilead has filed for United States Food and Drug Administration (FDA) approval of ledipasvir/sofosbuvir oral treatment, without interferon and ribavirin.

On October 10, 2014 the FDA approved the combination product ledipasvir 90 mg/sofosbuvir 400 mg called Harvoni.

Ledipasvir Application :

GS-5885 is an inhibitor of the hepatitis C virus (HCV) NS5A protein and exhibits potent suppression of genotype 1 HCV replicons. GS-5885 was well tolerated and resulted in median maximal reductions in HCV RNA ranging from 2.3 log(10) IU/ml (1 mg QD) to 3.3 log(10) IU/ml (10 mg QD in genotype 1b and 30 mg QD). E(max) modeling indicated GS-5885 30 mg was associated with>95% of maximal antiviral response to HCV genotype 1a. HCV RNA reductions were generally more sustained among patients with genotype 1b vs. 1a. Three of 60 patients had a reduced response and harbored NS5A-resistant virus at baseline. NS5A sequencing identified residues 30 and 31 in genotype 1a, and 93 in genotype 1b as the predominant sites of mutation following GS-5885 dosing. Ledipasvir (formerly GS-5885) is currently in Phase III clinical trials.
  • Country:
  • Business Type:
  • Market:
  • Founded Year:
  • Address:
  • Contact:Jackson Van
*Your name:
*Your Email:
*To:Yuancheng Group
*Subject:
*Message:
Enter between 20 to 3,000 characters. English only.     Characters : 0 / 3000
*Enter the secure code shown below Mfrbee security Image      Reload Image

submiting now We do inquire for you , please wait ...

Harvoni ( Sofosbuvir 400 mg/ Ledipasvir 90 mg)
Harvoni ( Sofosbuvir 400 mg/ Ledipasvir 90 mg)

Product Name: Harvoni Active Ingredient: Sofosbuvir / Ledipasvir Strength: 400 / 90 MG Dosage Form: Oral Tablets Indication: Chronic Hepatitis C Virus ...

Druds store limited.co.ltd

Ledipasvir
Ledipasvir

Beijing Mesochem Technology Co.,Ltd is one of the top level China ledipasvir manufacturers and suppliers, welcome to buy high purity and competitive price and harvoni, sofosbuvir ledipasvir, 1441674-54-9 Mesochem from our professional ...

Beijing Mesochem Technology Co., Ltd